BIOJECT MEDICAL TECHNOLOGIES INC·5

Feb 19, 12:25 PM ET

LOF PARTNERS LLC 5

5 · BIOJECT MEDICAL TECHNOLOGIES INC · Filed Feb 19, 2013

Insider Transaction Report

Form 5
Period: 2012-12-31
Transactions
  • Other

    Series G Preferred Stock

    2011-03-10+6,01250,335 total
    Exercise: $13.00From: 2011-03-10Common Stock (601,200 underlying)
  • Other

    Series G Preferred Stock

    2011-03-10+1,07610,741 total
    Exercise: $13.00From: 2011-03-10Common Stock (107,600 underlying)
Footnotes (4)
  • [F1]These securities are owned directly by Life Sciences Opportunities Fund II, L.P. and indirectly by Signet Healthcare Partners, LLC, the general partner of Life Sciences Opportunities Fund II, L.P., James C. Gale, the chief investment officer and manager of Signet Healthcare Partners, LLC, and SMW Investments I, LLC, the controlling member of Signet Healthcare Partners, LLC. Signet Healthcare Partners, LLC, SMW Investments I, LLC, and James C. Gale disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein.
  • [F2]These securities are owned directly by Life Sciences Opportunities Fund II (Institutional), L.P. and indirectly by Signet Healthcare Partners, LLC, the general partner of Life Sciences Opportunities Fund II (Institutional), L.P., James C. Gale, the chief investment officer and manager of Signet Healthcare Partners, LLC, and SMW Investments I, LLC, the controlling member of Signet Healthcare Partners, LLC. Signet Healthcare Partners, LLC, SMW Investments I, LLC, and James C. Gale disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein.
  • [F3]Series G Convertible Preferred Stock issued as stock dividend pursuant to the terms of a Purchase Agreement dated as of December 18, 2009. The Shares are convertible at any time by the purchasers into Commn Stock at the rate 100 shares of Common Stock per each shares of Series G Preferred Stock or $0.13 per share. LOF and LOFI paid for the Series G Preferred by the cancellation of the $600,000 outstanding principal amount of and $101,834.06 accrued interest through December 18, 2009 on the 2007 Convertible Subordinated Promissory Notes dated as of December 5, 2007
  • [F4]None

Documents

1 file
  • 5
    rrd370826.xmlPrimary